Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05357755 · ClinicalTrials.gov registry record · Phase 2
A Study of JNJ-77242113 for the Treatment of Moderate-to-Severe Plaque Psoriasis
A Phase 2 study, sponsored by Janssen Research & Development.
- Completed
- Registry status
- Phase 2
- Development phase
- 90
- Enrollment target
NCT05357755 is a Phase 2 study that has completed, run by Janssen Research & Development. The registered enrollment target is 90 participants.
The verdict
NCT05357755, a Phase 2 study, has completed, sponsored by Janssen Research & Development.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 90 participants
- Enrollment target
Study Summary
The purpose of the study is to evaluate the efficacy of an oral tablet formulation of JNJ-77242113 compared with placebo in participants with moderate-to-severe plaque psoriasis.
Interventions
- DRUG Placebo
- DRUG JNJ-77242113
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 90 participants |
| Start Date | 2022-06-13 |
| Est. Completion | 2023-04-10 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05357755
The ClinicalTrials.gov registry entry for NCT05357755 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 90 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Janssen Research & Development, which has 593 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT05357755 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05357755 about?
NCT05357755 is a clinical study titled "A Study of JNJ-77242113 for the Treatment of Moderate-to-Severe Plaque Psoriasis". The purpose of the study is to evaluate the efficacy of an oral tablet formulation of JNJ-77242113 compared with placebo in participants with moderate-to-severe plaque psoriasis.
What is the current status of trial NCT05357755?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 90 participants. The study started on 2022-06-13. Estimated completion is 2023-04-10.
What interventions are being tested in trial NCT05357755?
The interventions under investigation include: Placebo (DRUG), JNJ-77242113 (DRUG).
Who is sponsoring clinical trial NCT05357755?
This trial is sponsored by Janssen Research & Development, which has 593 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.